Behind the Paper: The Prognostic Impact of CXCR4 and TP53 Alterations on Zanubrutinib in Waldenström Macroglobulinemia
We analyzed 236 consecutive patients with WM treated with zanubrutinib at Dana‑Farber Cancer Institute, representing, to the best of our knowledge, the largest cohort reported to date.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Waldenström Macroglobulinemia Clinical Trials
- Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?